HAVCR2 and acute myeloid leukemia: We hypothesize that inhibiting the immune checkpoint TIM-3 may help alleviate the immunosuppressive effects of Treg cells and restore the antitumor immune activity of Teffs, making it a promising therapeutic approach for R/R AML.